A randomized, double blind, crossover study comparing Pliaglis (lidocaine/tetracaine) cream 7 percent/7 percent to placebo cream when applied for 60 minutes in the treatment of patients with postherpetic neuralgia.

Trial Profile

A randomized, double blind, crossover study comparing Pliaglis (lidocaine/tetracaine) cream 7 percent/7 percent to placebo cream when applied for 60 minutes in the treatment of patients with postherpetic neuralgia.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Lidocaine/tetracaine (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors ZARS Pharma
  • Most Recent Events

    • 14 Mar 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 02 Oct 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 02 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top